CoImmune Management Team
13 Team Members
CoImmune has 13 executives. CoImmune's current President is Jeffrey D Abbey.
You May Also Like
Traversa Therapeutics is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi anti-cancer therapeutics. The company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of platform delivery technology, as well as advancement of therapeutic programs for the treatment of leukemia and glioblastoma.
Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.
Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.
ImmuRx is focused on cancer and chronic infectious disease by stimulating both the innate and adaptive halves of the immune system. Per the company, ImmuRx has demonstrated significantly greater immune responses and greater therapeutic benefit than most competing adjuvants in a wide variety of disease indications.
Inimex Pharmaceuticals, Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), first in class drugs that selectively trigger the body's innate defenses without causing inflammation. IDR products have major market potential for infectious disease, cancer, and inflammatory disease. These products will reduce morbidity and mortality in the rapidly growing population of immune suppressed and elderly patients who are "at-risk" for these disorders. IDR products will also benefit healthcare payors by reducing costs associated with hospitalization. Inimex' lead IDR product IMX942 targets a broad spectrum of life-threatening hospital infections, many of which are caused by antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). IMX942 is active against both normal and drug-resistant bacteria and its ability to stimulate host innate immune defenses is not susceptible to bacterial antibiotic resistance mechanisms. The first clinical indication for IMX942 will be the prevention of infections associated with cancer chemotherapy-induced immune suppression. nnAdditional IDR product candidates will be developed for distinct disease areas, with an emphasis on inflammatory disease and demonstration of the potential for orally available IDR dosage forms.
JADO aims to become the leader in the emerging field of Raft intervention therapeutics, through the development of pharmaceutical products with potential for treating a range of human diseases. RAFTs are sub-compartments of cell membranes that play an integral role in key biological pathways. Using its drug development platform, called Raft Intervention Technology, JADO is exploiting new insights and understanding of cell membrane chemistry and organization that aims to enable us to address difficult to treat diseases, such as allergies (atopic dermatitis, asthma), viral and bacterial infections, cancer, neurodegenerative diseases (Alzheimer's) and metabolic illnesses (diabetes, lipid storage diseases).
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.